RankAlpha logo
Back to Rankings

CTNM

Contineum TherapeuticsD
Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-21
View Chart
Current thesis
The constructive case is balance-sheet-backed optionality around PIPE-791: patient dosing has started in PROPEL-IPF, chronic-pain topline is due in Q2 2026, and cash runway extends into mid-2029, giving CTNM time to reach more meaningful clinical inflections without obvious near-term financing stress [#PR-2026-03-05][#10-K-2026-03-05].
Posture
Defensive
Lead driver
Momentum
What changed
Momentum remains the lead driver in the composite, 7D delta -24.5.
What can break
Cash runway is improved but not permanent; clinical setbacks could reopen dilution risk.
Momentum
64
Value
41
Sentiment
45
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $13.00 · Bull $19.00 · Bear $8.00
Data freshness
Prices
As of 2026-07-21
Fundamentals
As of 2026-07-21 • Vendor: Data Vendor v1
Scores
As of 2026-07-21 • Model: HYBRID_IC_RP
AI Memo
As of 2026-04-15 • Model: RankAlpha Sentiment Codex
Investment thesis
As of 2026-07-21
Supporting evidence
What
Grade D · Defensive
Confidence Medium · Net Neutral
Target $22.33
Why
Momentum64 · Δ7d -24.5
Value41 · Δ7d +0.1
Sentiment45 · Δ7d +4.6
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Lead driver: Momentum · See technicals
Momentum
64
26% active weight
Current posture
7d trendSoftening
Δ7d
-24.5
Δ21d
+38.9
Value
41
39% active weight
Current posture
7d trendFlat
Δ7d
+0.1
Δ21d
-0.0
Sentiment
45
34% active weight
Current posture
7d trendImproving
Δ7d
+4.6
Δ21d
+5.9
Why this grade

Composite grade D. Momentum 64.1 / Value 41.1 / Sentiment 44.7

Fundamentals (TTM)
As of 2026-07-21
Market Cap
$519.67M
Beta
-
Shares Out
37.39M
P/E (TTM) · Derived
-6.4
P/S (TTM)
-
P/FCF (TTM) · Derived
-7.26
Rev YoY
-100.0%
EPS YoY
-37.4%
Gross Margin
+99.6%
Op Margin
-
Net Debt
-$254.65M
Current Ratio
38.00
As of 2026-07-21 • Updated nightlySource: Internal modelMethodology